Johnson & Johnson’s pharmaceutical subsidiary Janssen and Germany-based pharmaceutical company Grünenthal have sued Watson Laboratories for infringing patents related to painkiller Nucynta (tapentadol hydrochloride).
The US District Court for the District of New Jersey has granted Mylan its motion for a permanent injunction against GlaxoSmithKline’s (GSK’s) Paroxetine CR.
The Medicines Patent Pool (MPP) has announced seven new sub-licensing agreements to make generic HIV medicines atazanavir (ATV) and dolutegravir (DTG).
Novartis’s eye care unit Alcon Pharmaceuticals has sued Hyderabad-based Aurobindo Pharma for infringing two patents covering its eye drop solution Vigamox (moxifloxacin hydrochloride) at the US District Court for the District of Delaware.
US-based Acorda Therapeutics has sued Actavis for infringing four patents covering its multiple sclerosis (MS) drug Ampyra (dalfampridine).
Pfizer has launched a lawsuit against Aurobindo Pharma accusing the Indian pharmaceutical company of infringing patents related to an antibiotic used to treat skin infections.
New York-headquartered Forest Laboratories has filed suit against Indian company Aurobindo Pharma to protect Namenda, a treatment for moderate to severe Alzheimer’s disease.
The Indian Patent Office has rejected a patent application for an anti-cancer drug for the second time, paving the way for generic versions to potentially enter the market.
Stem cell research companies in Canada and Australia have teamed up to support increased research and development in both countries.
Irish-based drug manufacturer Actavis has settled its patent dispute with Zydus Pharmaceuticals.